Members

The WGND is composed of diverse interested stakeholders in TB drug development, including those working in TB drug R&D, regulators, public health workers, funders, community representatives, advocates and policy-makers.

The WGND membership rests with individuals, not institutions. Thus, the WGND has no "lead agency" and is not dominated by any institution or group of institutions. Members represent the private and public sectors and come from diverse geographical locations.

Apply Now Learn More View Core Group

Task Forces

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Current Members


Name Organization Country
Tarek Aboul-Fadl Medicinal Chemistry, Assiut University Egypt
Ibrahim Abubakar University College Londond and MRC Clinical Trials Unit, London United Kingdom
Neha Agarwal Clinton Health Access Initiative United States
Zahoor Ahmed National T.B Control Programme Pakistan
Asaad Khalid Ahmed National Center for Research Sudan
Avishek Anant National Institute of Immunology India
Koen Andries Tibotec Belgium
Asghar Arif TB Association Charsadda Pak Pakistan
Yossef Av-Gay University of British Columbia Canada
Venkataraman Balasubramanian AstraZeneca R&D India India
Tanjore Balganesh AstraZeneca R&D India India
Lluís Ballell GlaxoSmithKline Tres Cantos Spain
Cathy Bansbach Bill & Melinda Gates Foundation United States
Jing Bao Henry M Jackson Foundation for the Advancement of Military Medicine at DAIDS/NIAID/NIH United States
Belen Barrio Sanofi-Aventis R&D France
David Barros GlaxoSithKline Spain
Clifton Barry National Institutes of Health (NIH), NIAID United States
Robert Bates GlaxoSmithKline Spain
Anthony Baughn University of Minnesota United States
Maria Beconi TB Alliance United States
Edward Berry SUNY Upstate Medical University United States
Sanjib Bhakta The Institute of Structural and Molecular Biology, Birkbeck, University of London United Kingdom
Khadar Bhatcha India
William Bishai Johns Hopkins School of Medicine United States
Gill Black Sustainable Livelihoods Foundation South Africa
Jonathan Blackburn University of Cape Town South Africa
Amy Bloom United States Agency for International Development United States
Martin Johan Boeree PanACEA Consortium and the Radboud University Nijmegen Medical Centre Netherlands
Florence Bordon-Pallier sanofi-aventis France
Helena Boshoff National Institutes of Health United States
Renaud Boulanger Canada
Yap Boum II Epicentre/MSF Uganda
Jim Boyce National Institute of Allergy and INfectious Diseases United States
Jim Boyce NIAID United States
Barry Bunin Collaborative Drug Discovery United States
Pere-Joan Cardona Institut Germans Trias i Pujol (IGTP) Spain
Patrizia Carlevaro Otsuka-SA South Africa
Alexandra Carreau Sanofi-adventis R&D France
Allen Casey Infectious Disease Research Institute United States
Gail Cassell Research America United States
Kenneth Castro U.S. Centers for Disease Control and Prevention United States
Joan A. Cayla Spain
Richard Chaisson Johns Hopkins University Center for TB Research United States
William Chamberlin Self - (Texas Tech University Health Sciences Center) United States
Sang Nae Cho Yonsei University College of Medicine South Korea
Sidharth Chopra SRI International United States
Isabelle Cieren-Puiseux sanofi-aventis France
Jeffery Cirillo Texas A&M Health Science Center United States
Polly Clayden HIV i-Base United Kingdom
Stewart Cole École Polytechnique Fédérale de Lausanne (EPFL) Switzerland
Christopher Cooper Global Alliance for TB Drug Development (TB Alliance) United States
Michael Cynamon VAMC, SUNY, Upstate Medical University United States
Kobina Bosumtwi Dadzie wiljok Childaid and health organization Ghana
Aboubacar Sidiki DAFFE Université Cheikh Anta DIOP Senegal
Mary Ann de Groote Colorado State University United States
Jurriaan de Steenwinkel Erasmus MC Netherlands
Oscar Della Pasqua GlaxoSmithKline United Kingdom
Brigitte Demers sanofi-aventis France, Metropolitan
Neeraj Dhar Global Health Institute, Swiss Federal Institute of Technology Lausanne Switzerland
Andreas Diacon University of Stellenbosch South Africa
Marcio Dias University of Sao Paulo Brazil
Thomas Dick National University of Singapore Singapore
Chris Dippel Peloton Partnering, SP United States
Noroi Doi Japan Anti-Tuberculosis Association; Research Institute of Tuberculosis Japan
Martin Dolezal Charles University in Prague, Faculty of Pharmacy in Hradec Kralove Czech Republic
Valerie Flore Donkeng Donfack Laboratory of Phytobiochemistry and Medicinal Plants Study Cameroon
Andriy Dudnyk National Medical University of Vinnytsia, Ukraine Ukraine
Carol Dukes Hamilton Family Health International United States
Ken Duncan Bill & Melinda Gates Foundation United States
Chris Edlin iThemba Pharmaceuticals South Africa
Leo Einck Sequella, Inc. United States
Kolawole Ekanoye Advocates for Health and Development Initiative Nigeria
Dr Muhammad Farooq Govt of Pakistan Pakistan
Bernard Fourie University of Pretoria South Africa
Scott Franzblau Institute for Tuberculosis Research, University of Illinois at Chicago United States
Maria Freire Lasker Foundation United States
Joel Freundlich UMDNJ - New Jersey Medical School United States
James Frincke Hollis Eden Pharmaceuticals United States
Jennifer Fujii Vertex Pharmaceuticals United States
Barry Furr Astrazeneca United States
Elizabeth Gardiner TB Alliance United States
Sylvie Garneau-Tsodikova University of Michigan United States
Federico Gómez de las Heras GlaxoSmithKline Spain
Lawrence Geiter Otsuka Pharmaceutical Company United States
Bolin Geng Merrimack Pharmaceuticals United States
Shahin Gharakhanian Vertex Pharmaceuticals United States
Jan Gheuens Bill & Melinda Gates Foundation United States
Ann Ginsberg TB Alliance United States
Marc Gitzinger BioVersys AG Switzerland
Bob Goldman RCG Consulting United States
Martin Graham PKPD Bioscience United States
Hugo Cesar Gramajo Instituto de Biologia Molecular y Celular de Rosario
David Greeley TB Alliance United States
Jacques Grosset Johns Hopkins University School of Medicine United States
Trudy Grossman TetraPhase Pharmaceuticals United States
Malgosia Grzemska World Health Organization Switzerland
Tawanda Gumbo University of Texas Southwestern Medical Center at Dallas United States
Shashank Gupta Johns Hopkins University United States
Juan David Guzman Birkbeck College United Kingdom
Debra Hanna CPTR, Critical Path Institute United States
Nii Nortey Hanson-Nortey Ghana Health Service Ghana
Mark Harrington Treatment Action Group United States
Norbert Heinrich Universtiy of Munich / PanACEA Germany
Sonja Henne LMU (University of Munich) Germany
Anneke Hesseling Desmond Tutu TB Centre South Africa
Philip Hipskind Eli Lilly and Company; Lilly Research Laboratories United States
Michael Hoelscher Ludwig-Maximilians-University Germany
C. Robert Horsburgh Boston University School of Public Health United States
Gary Horwith Sequella, Inc. United States
Robert Husson Children's Hospital Boston/Harvard Medical School United States
Heather Ignatius TB Alliance United States
Daniela Jabes NeED Parma Italy
Mary Jackson Colorado State University United States
Josef Jampilek University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Chemical Drugs Czech Republic
Amina Jindani St. George's, University of London United Kingdom
kr john SRM medicacl college India
Yadav Prasad Joshi Biodyss and Journal Infection in Developing Countries France
Rajender Kamboj Lupin Limited India
Bavesh Kana University of the Witwatersrand/National Health Laboratory Service South Africa
Takushi Kaneko TB Alliance United States
Shashi Kant UT Southwestern Medical Center United States
Gilla Kaplan UMDNJ - New Jersey Medical School United States
Petros Karakousis Johns Hopkins University School of Medicine United States
Victoria Kasprowicz K-RITH (KwaZulu-Natal Research Institute for Tuberculosis and HIV) South Africa
Hiromu Kawakubo Asahi Kasei Chemicals Corporation Japan
Edward Kesicki Infectious Disease Research Institute United States
Ahmadul Khan Ahmadul Hasan Khan Bangladesh
Basharat Khan National TB Control Program Pakistan
Sang Jae Kim Korean Institute of Tuberculosis South Korea
Sergey Koren JSC Pharmasyntez Russia
Anil Koul Johnson and Johnson Belgium
Galyna Kutsyna Luhansk State Medical University Ukraine
Gyanu Lamichhane Johns Hopkins University United States
Barbara Laughon National Institute of Allergy and Infectious Diseases, NIH, DHHS United States
Didier Leboulleux sanofi-aventis France
Anne Lenaerts Colorado State University United States
Erica Lessem Treatment Action Group United States
Francisco Leyva NIAID-NIH United States
Christian Lienhardt WHO Stop TB Partnership Research Movement Senegal
Christopher Locher Vertex Pharmaceuticals United States
Nino Lomtadze National Center for Tuberculosis and Lung Diseases Georgia
James Love Knowledge Ecology International (KEI) United States
Doug Lowrie Fudan University's Shanghai Public Health Clinical Center China
Shichun Lun Johns Hopkins University School of Medicine United States
Htay Lwin NTP,Myanmar Myanmar (Burma)
Zhenkun Ma TB Alliance United States
Parameshwar Makam Pondicherry University India
Mamodikoe Makhene NIH United States
ALICK CHIPIMO MAKIYI Grassroots Movement for Health and Development (GMHD) Malawi
Albert Makone Community Working Group on Health Zimbabwe
Teto Fondacaro Mamona Programme National de lutte contre la Tuberculose Democratic Republic Of Congo (Zaire)
Shekhar Mande National Centre for Cell Science India
Bonita Mangura New Jersey Medical School Global TB Institute at UMDNJ United States
Mohammad Hassan Mashori Fundamental Human Rights & Rural Development Association FHRRDA Pakistan
Stephen Matlin Global Forum for Health Research Switzerland
Maggie McCammon University of Michigan United States
David McNeeley Medical Service Corportation International (MSCI) United States
Khisimuzi Mdluli TB Alliance United States
Arun Kumar Mishra University of Birmingham United Kingdom
Dennis Mitchison St Georges. University of London United Kingdom
Carole Mitnick Harvard Medical School United States
Valerie Mizrahi UCT-Institute of Infectious Disease and Molecular Medicine South Africa
Heinz Moser Achaogen United States
Roger Moses iThemba Pharmaceuticals United Kingdom
Peter Mueller Vertex Pharmaceuticals United States
Ute Muh Vertex Pharmaceuticals United States
Paul Murima Global Health Institute, Ecole Polytechnique Fédérale de Lausanne Switzerland
Benson Muriuki Center for the Empowerment Of The Local Herbalist-Celoh Kenya Kenya
Carol Nacy Sequella, Inc. United States
Payam Nahid University of California, San Francisco United States
P. R. Narayanan Tuberculosis Research Centre, Chennai (retired) India
Edward Nardell Partners in Health United States
Carl Nathan Weill Cornell Medical College United States
Michaela Nielsen Michaela Nielsen, Regulatory Affairs United States
Eric Nuermberger Johns Hopkins University United States
Rick O'Brien Foundation for Innovative New Diagnostics Switzerland
Ronan O'Toole Trinity College Dublin Ireland
DOROTHY ODHIAMBO International Community of Women Living with HIV in Kenya ( ICW-K) Kenya
Matti Ojanen AstraZeneca PLC United Kingdom
Masaji Okada Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center
Iain Old Ecole Polytechnique Federale de Lausanne (EPFL) Switzerland
lemouldc OLIVIER lemouldclar United States
Philip Onyebujoh WHO/Special Programme for Research and Training in Tropical Diseases (TDR) Switzerland
Diane Ordway Colorado State University United States
Ian Orme Colorado State University United States
Regina Osih Clinton Health Access Initiative South Africa
Nelson Otwoma Positive Familes Network (+FN) Kenya
Prasit Palittapongarnpim Mahidol University Thailand
Martin Pan Otsuka Novel Products United Kingdom
Rogelio Hernandez Pando National Institute of Medical Sciences and Nutrition, Mexico Mexico
Frances Pappas TB Alliance United States
Shreemanta Parida Vaccine Grand Challenge Program & Ministry of Science (India) India
Tanya Parish Infectious Disease Research Institute United Kingdom
PRASAD PASAM SHAR TECHNOLOGIES GROUP India
Fernando Pavan São Paulo State University, UNESP, Brazil Brazil
Shaaretha Pelly Center for Tuberculosis Research Johns Hopkins University United States
Liyanage Perera National Institutes of Health United States
Kevin Pethe Institut Pasteur-Korea South Korea
Sabai Phyu Novartis Institute for Tropical Diseases Singapore
Matthew Price Harvard School of Public Health United States
Marina Protopopova Sequella, Inc. United States
DR.DHANJI RAJANI MICROCARE LABOARATORY India
Ravishankar Ramachandran CSIR-Central Drug Research Institute, Lucknow, India India
Santiago Ramón García The University of British Columbia Canada
Kanury Rao International Centre for Genetic Engineering & Biotechnology-New Delhi India
Mario Raviglione World Health Organization Switzerland
Klaus Reither Swiss Tropical and Public Health Institute Tanzania
John Rex AstraZeneca R&D United Kingdom
Kyu Rhee Weill Cornell Medical College United States
Robert Ridley WHO/Special Programme for Research and Training in Tropical Diseases (TDR) Switzerland
Brian Robertson Imperial College London United Kingdom
Doris Rouse RTI International United States
Samir Roy Government Medical College, Bhavnagar India
David Russell Cornell University United States
Sandeep Saluja Sandeep Saluja India
ROBERTO SALVINO Philippines
Christopher Sassetti University of Massachusetts Medical School United States
KAMPASATI SATYANARAYANA YUVABHARATH SOCIETY India
Dario Scaramuzzi R-Evolution Group EEIG Italy
Dirk Schnappinger Weill Cornell Medical College United States
Cherise Scott Stop TB Partnership Working Group on New TB Drugs United States
Boitumelo Semete Council of Scientific Industrial Research (CSIR) in South Africa South Africa
Carleton Sherman UT Southwestern Medical Center United States
David Sherman Seattle Biomedical Research Institute United States
Tado Shimao JATA Research Institute of Tuberculosis (RIT) Japan
Gerald Shipps New Venture Fund United States
Gerald Siuta TB Alliance United States
Christine Sizemore National Institute of Allergy & Infectious Diseases (NIH) United States
Peter Small Bill & Melinda Gates Foundation United States
Nelly Solomonia National Center for Tuberculosis and Lung Diseases Georgia
Melvin Spigelman TB Alliance United States
Martin Springsklee Bayer Healthcare United States
Hulda Swai Council of Scientific Industrial Research (CSIR) in South Africa South Africa
Javid Syed Treatment Action Group United States
John Szumowski University of Washington United States
Rajneesh Taneja TB Alliance United States
Gail Tauscher NIH, NIAID United States
John Thomson Vertex Pharmaceuticals United States
Simon Tiberi Barts Healthcare NHS Trust United Kingdom
Tamari Trapaidze Welfare Foundation Georgia
Oleg Tsodikov University of Michigan United States
Manjunatha Ujjini Novartis Institute for Tropical Diseases Singapore
Anna Upton TB Alliance United States
Astrid Van der Sar VU University medical center Netherlands
Christo van Niekerk TB Alliance South Africa
Omar Vandal Bill and Melinda Gates Foundation United States
Brian VanderVen Cornell University United States
Wim Vandevelde European AIDS Treatment Group (EATG) Portugal
Andrew Vernon U.S. Centers for Disease Control and Prevention United States
Laura Via NIAID United States
Dalene von Delft TB Proof South Africa
Todd Waldman Easton Associates United States
Kristina Wallengren THINK South Africa
Robert Wallis Pfizer Inc United States
Gerhard Walzl Stellenbosch University South Africa
Joshua Wamboga The AIDS Support Organisation (TASO) Uganda
Steve Wandiga KEMRI/CDC Kenya
Tiansheng Wang Vertex Pharmaceuticals United States
Peter Warner Bill and Melinda Gates Foundation United States
Charles Wells Otsuka Pharmaceutical Company United States
Richard White London School of Hygiene and Tropical Medicine United Kingdom
Nicolas Willand Institut Pasteur Lille France
Sharon Williams National Institute for Allergy and Infectious Diseases, NIH United States
Claire Wingfield PATH United States
Jerome Zeldis Celgene United States
Xuelian Zhang Fudan University China
Ying Zhang Johns Hopkins University United States
Oren Zimhony Kaplan Medical Center, The School of Medicine Hebrew University Israel
Daniel Zollinger okklo life sciences Netherlands

New Members


The Working Group pipeline is open to anyone who is developing a TB drug. If you would like to become a member, please submit an application.

Apply Now

Questions? Contact Us